论文部分内容阅读
目的:对雷贝拉唑治疗幽门螺杆菌阳性消化性溃疡的临床效果进行观察。方法:选取2012年11月--2013年11月间于我院进行疾病治疗的幽门螺杆菌阳性消化性溃疡患者100例,随机分为两组。对照组患者采取奥美拉唑药物治疗,观察组患者采取雷贝拉唑药物治疗。后对两组患者的临床疗效进行比较。结果:观察组中的幽门螺杆菌阳性消化性溃疡患者临床疾病愈合率66.00%明显高于对照组52.00%,两组数据有明显差异,p<0.05。结论:采取雷贝拉唑药物对幽门螺杆菌阳性消化性溃疡疾病进行治疗,有较好的临床效果。
Objective: To observe the clinical effect of rabeprazole in the treatment of Helicobacter pylori positive peptic ulcer. Methods: One hundred patients with Helicobacter pylori positive peptic ulcer who were treated in our hospital from November 2012 to November 2013 were randomly divided into two groups. Patients in the control group were treated with omeprazole, and patients in the observation group were treated with rabeprazole. After comparing the clinical efficacy of two groups of patients. Results: The clinical cure rate of H. pylori-positive peptic ulcer patients in the observation group was significantly higher than that of the control group (66.00% vs 52.00%), with significant difference between the two groups (p <0.05). Conclusion: Taking rabeprazole for the treatment of Helicobacter pylori positive peptic ulcer disease has a good clinical effect.